+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy



Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy



Journal of the American Society of Nephrology 27(11): 3459-3468



Diabetic nephropathy (DN) is the leading cause of ESRD worldwide. Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN. Preclinical studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN. To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy. In total, 256 subjects with an eGFR between 25 and 60 ml/min per 1.73 m2 and macroalbuminuria defined by a urinary albumin-to-creatinine ratio >300 mg/g, were randomly assigned 3:1, respectively, to receive PF-00489791 (20 mg) or placebo orally, once daily for 12 weeks. Using the predefined primary assessment of efficacy (Bayesian analysis with informative prior), we observed a significant reduction in urinary albumin-to-creatinine ratio of 15.7% (ratio 0.843; 95% credible interval 0.73 to 0.98) in response to the 12-week treatment with PF-00489791 compared with placebo. PF-00489791 was safe and generally well tolerated in this patient population. Most common adverse events were mild in severity and included headache and upper gastrointestinal events. In conclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigation as a novel therapy to improve renal outcomes in DN.

(PDF emailed within 0-6 h: $19.90)

Accession: 058546503

Download citation: RISBibTeXText

PMID: 27113485

DOI: 10.1681/ASN.2015050473


Related references

Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrology Dialysis Transplantation 11(1): 182-185, 1996

Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrology, Dialysis, Transplantation 11(1): 182-185, 1996

Determination of albuminuria in type 1 and type 2 diabetic patients with microproteinuria and overt nephropathy comparative evaluation between a radial immunodiffusion procedure and a highly sensitive radioimmunoassay. Ricerca in Clinica e in Laboratorio 17(2): 171-179, 1987

Control of albuminuria in overt diabetic nephropathy: durability counts. Nephrology, Dialysis, Transplantation 31(9): 1371-1373, 2018

Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. Diabetes Care 26(2): 502-509, 2003

Early restriction of dietary protein intake reduces albuminuria in type i diabetic patients with clinical nephropathy. Belfiore, F , G M Molinatti And J R Williamson (Ed ) Frontiers in Diabetes, Vol 8 Vascular And Neurologic Complications Of Diabetes Mellitus; 2nd International Diabetes Conference, Florence, Italy, November 7-9, 1985 Xi+255p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 210-212, 1987

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocrine Journal 61(2): 159-166, 2014

Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. Kidney International Reports 3(6): 1316-1327, 2018

Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria?. American Journal of Cardiovascular Disease 6(2): 66-69, 2016

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. Journal of International Medical Research 33(6): 677-686, 2005

Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Research & Clinical Practice 58(2): 123-129, 2002

Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. International Journal of Obesity 13(2): 203-211, 1989

Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. American Journal of Kidney Diseases 40(3): 489-494, 2002

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal Medicine 138(7): 542-549, 1 April, 2003

Enalapril reduces albuminuria in hypertensive and normotensive models of diabetic nephropathy. Diabetologia 30(7): 510A, 1987